A Phase 1 interventional study of SAR446523 in Plasma Cell Myeloma Refractory, sponsored by Sanofi. Recruiting at 19 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Sanofi · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Multiple Myeloma by Sanofi — 3 open to participants now, 8 under way, 3 of them phase 3. Multiple Myeloma · Sanofi.
Among the 39 studies in Multiple Myeloma by Sanofi, this one is the 13th largest by planned enrollment of the 34 interventional ones that give a count, is the only one that started in 2024, is one of 10 in phase 1, and was the 39th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →3 of the 39 studies in Multiple Myeloma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Australia, France and 7 more countries
Ages 18+
Sanofi · Sites in United States, Australia, Brazil and 14 more countries
Ages 18+
By country, each count listing its studies:
Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 17 · Phase 3 7
First in 2002; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 87 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 56 across the 34 interventional studies, 423 across the 4 observational. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
3 of the studies in Multiple Myeloma by Sanofi that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT06356571SanofiA Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | 2027-04-01 |
| NCT04643002SanofiIsatuximab in Combination With Novel Agents in RRMM - Master Protocol | 2027-09-13 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies in Multiple Myeloma by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a first-in-human study of SAR446523 conducted in patients with RRMM.
The study consists of two parts:
Dose escalation (Part A): In this part, up to several dose levels (DLs) of SAR446523 will be explored to determine the maximum administered dose (MAD), maximum tolerated dose (MTD), and recommended dose range (RDR) of 2 dose regimens which will be tested in the dose optimization part.
Dose optimization (Part B): In this part, participants will be randomly assigned in a 1:1 ratio using interactive response technology (IRT) to either one of the chosen dose regimens of SAR446523 (determined from data coming from Part A), to determine the optimal dose as the recommended phase 2 dose (RP2D) of SAR446523.
The study will be considered ongoing until the last participant last visit has occurred. Participants will be allowed to continue therapy until disease progression, unacceptable AEs, participant or Investigator's request to discontinue treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Dose escalation (Part A)
Dose optimization (Part B)
Exclusion Criteria:
-Participants are excluded from the study if any of the following criteria apply: performance status (ECOG PS) of 2 or greater.
The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive SAR446523
Drug: SAR446523
Participants will receive SAR446523 Dose-1
Drug: SAR446523
Participants will receive SAR446523 Dose-2
Drug: SAR446523
Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)
Incidence of Dose Limiting Toxicities (DLTs)- Dose escalation (Part A)
The incidence of DLTs will be evaluated using NCI CTCAE version 5.0 criteria.
Time frame: Cycle 1 (28 days)
Overall response rate (ORR) - Dose optimization (Part B)
ORR is defined as the proportion of participants with sCR, CR, VGPR, and PR assessed as per Investigator according to the 2016 IMWG response criteria.
Time frame: 24 months after the Last Participant In (LPI)
Number of participants with treatment emergent adverse events (TEAEs), injection related reactions (IRRs), injection site reactions (ISRs), serious adverse events (SAEs), adverse event of special interests (AESIs)
Measured as per NCI CTCAE v 5.0
Time frame: From the signing of informed consent to 30 days after the date of the last study treatment administration i.e., approximately 5 years
Change from baseline in laboratory abnormalities
Measured as per NCI CTCAE v 5.0.
Time frame: From the signing of informed consent to 30 days after the date of the last study treatment administration i.e., approximately 5 years
ORR- Dose escalation (Part A)
ORR defined as the proportion of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) assessed as per Investigator according to the 2016 International Myeloma Working Group (IMWG) response criteria.
Time frame: 24 months after the Last Participant In (LPI)
VGPR or better rate
VGPR or better rate defined as the proportion of participants with sCR, CR, and VGPR assessed as per Investigator according to the 2016 IMWG response criteria.
Time frame: 24 months after the Last Participant In (LPI)
Clinical benefit rate (CBR)
CBR defined as the rate of participants with confirmed sCR, CR, VGPR, or PR at any time or minimal response (MR) of at least 6 months from the first IMP administration determined per 2016 IMWG response criteria.
Time frame: 24 months after the Last Participant In (LPI)
Duration of response (DoR)
DoR defined as the time from the date of the first response (PR or better) to the date of first documentation of progressive disease (PD) as defined in the 2016 IMWG response criteria, or date of death, whichever occurs first.
Time frame: 24 months after the Last Participant In (LPI)
Time to response (TTR)
TTR defined as the time from the first administration of study IMP to the date of first response (PR or better) that is subsequently confirmed.
Time frame: 24 months after the Last Participant In (LPI)
Progression free survival (PFS)
PFS defined as the time interval from the date of first administration of study IMP to the date of first documentation of PD per 2016 IMWG criteria assessed by study Investigator, or date of death from any cause, whichever comes first.
Time frame: 24 months after the Last Participant In (LPI)
Minimal residual disease (MRD) status negativity
MRD status negative by nextgeneration sequencing (NGS) in bone marrow of participants with a response of CR (or VGPR in case of suspected interference).
Time frame: 24 months after the Last Participant In (LPI)
Number of participants with symptomatic AEs -Part B
The incidence and evaluation of symptomatic AEs from participants' perspective will be measured by using specific items from National Cancer Institute (NCI) patient-reported outcome (PRO) common terminology criteria for adverse events (CTCAE) library.
Time frame: From Cycle 1 Day 1 to 30 days after the date of the last study treatment administration i.e., approximately 5 years
Change from baseline in overall side effect bother as measured by the Functional Assessment of Cancer Therapy item 5 (FACT-GP5)- Part B
The FACT GP5 is an assessment focused on the overall side effect impact to inform the tolerability of a treatment. The FACT GP5 ("I am bothered by side effects of treatment") responses are given on a 5 point Likert type scale recalling the past 7 days. Higher scores indicate a higher degree of side effect bother.
Time frame: From Cycle 1 Day 1 to 30 days after the date of the last study treatment administration i.e., approximately 5 years
Maximum observed concentration (Cmax)
To characterize the pharmacokinetics (PK) of SAR446523.
Time frame: Multiple timepoints from Cycle 1 Day 1 to Cycle 1 Day 8 (cycle 1=28 days)
First time to reach Cmax (tmax)
To characterize the PK of SAR446523.
Time frame: Multiple timepoints from Cycle 1 Day 1 to Cycle 1 Day 8 (cycle 1=28 days)
Area under the concentration versus time curve calculated from 0 to 168 hours (AUC0-168h)
To characterize the PK of SAR446523.
Time frame: Multiple timepoints from Cycle 1 Day 1 to Cycle 1 Day 8 (cycle 1=28 days)
Proportion of participants with presence of anti-drug antibody (ADA) against SAR446523.
To evaluate potential immunogenicity.
Time frame: From Cycle 1 Day 1 to 30 days after the date of the last study treatment administration i.e., approximately 5 years
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Oct 2024 (actual). Primary completion is estimated for May 2031, 78 months after the start.
Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 78 months is above that.
Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.